Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 5, 2014, Pages 1495-1502

  Roberts, Jason A ^a,b,c   Udy, Andrew A ^a,d   Jarrett, Paul ^b   Wallis, Steven C ^a   Hope, William W ^c   Sharma, Raman ^e   Kirkpatrick, Carl M J ^f   Kruger, Peter S ^g   Roberts, Michael S ^h   Lipman, Jeffrey ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d ALFRED HOSPITAL   (Australia)

^e LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^f MONASH UNIVERSITY   (Australia)

^g PRINCESS ALEXANDRA HOSPITAL   (Australia)

^h UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Antibiotics; Microdialysis; Monte Carlo simulations; Pharmacodynamics; PK

Indexed keywords

CEFAZOLIN; SERUM ALBUMIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ALBUMIN BLOOD LEVEL; APACHE; ARTICLE; BLOOD; BODY WEIGHT; CLINICAL ARTICLE; CRITICALLY ILL PATIENT; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; HUMAN; IN VIVO STUDY; INTENSIVE CARE UNIT; INTERSTITIAL FLUID; MALE; MICRODIALYSIS; MONTE CARLO METHOD; OBSERVATIONAL STUDY; PATIENT REFERRAL; SKIN INJURY; SOFT TISSUE INJURY; STAPHYLOCOCCUS AUREUS; SUBCUTANEOUS TISSUE; VOLUME OF DISTRIBUTION; ADOLESCENT; BACTERIAL INFECTIONS; BIOSTATISTICS; CHEMISTRY; COMPLICATION; COMPUTER SIMULATION; CRITICAL ILLNESS; DRUG EFFECTS; INJURY; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; PLASMA; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BIOSTATISTICS; CEFAZOLIN; COMPUTER SIMULATION; CRITICAL ILLNESS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MONTE CARLO METHOD; PLASMA; STAPHYLOCOCCUS AUREUS; SUBCUTANEOUS TISSUE; WOUNDS AND INJURIES; YOUNG ADULT;

EID: 84929720221     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku564     Document Type: Article

References (35)

1. Kollef MH, Sherman G,Ward S et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-74.
2. Kumar A, Roberts D, Wood KE et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-96.
3. Roberts JA, Paul SK, Akova M et al. DALI: defining antibiotic levels in intensive care unit patients: are current b-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 2014; 58: 1072-83.
4. Vincent JL, Rello J, Marshall J et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302:2323-9.
5. Roberts JA, Kruger P, Paterson DL et al. Antibiotic resistance-what's dosing got to do with it? Crit Care Med 2008; 36: 2433-40.
6. Roberts JA, Abdul-Aziz MH, Lipman J et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 2014; 14: 498-509.
7. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009; 37: 840-51.
8. Udy AA, Baptista JP, Lim NL et al. Augmented renal clearance in the ICU:results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations. Crit Care Med 2014; 42: 520-7.
9. Udy AA, Roberts JA, Boots RJ et al. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010; 49: 1-16.
10. Udy AA, Varghese JM, Altukroni M et al. Subtherapeutic initial b-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 2012; 142: 30-9.
11. Baptista JP, Udy AA, Sousa E et al. A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance. Crit Care 2011; 15: R139.
12. Carlier M, Carrette S, Roberts JA et al. Meropenem and piperacillin/ tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? Crit Care 2013; 17: R84.
13. Fuster-Lluch O, Geronimo-Pardo M, Peyro-Garcia R et al. Glomerular hyperfiltration and albuminuria in critically ill patients. Anaesth Intensive Care 2008; 36: 674-80.
14. Finfer S, Bellomo R, Boyce N et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350:2247-56.
15. Ulldemolins M, Roberts JA, Rello J et al. The effects of hypoalbuminaemia on optimising antibiotic dosing in critically ill patients. Clin Pharmacokinet 2011; 50: 99-110.
16. Chaurasia CS, Muller M, Bashaw ED et al. AAPS-FDAWorkshop White Paper: microdialysis principles, application, and regulatory perspectives. J Clin Pharmacol 2007; 47: 589-603.
17. Joukhadar C, Frossard M, Mayer BX et al. Impaired target site penetration of b-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 2001; 29: 385-91.
18. Roberts JA, Roberts MS, Robertson TA et al. Piperacillin penetration into tissue of critically ill patients with sepsis-bolus versus continuous administration? Crit Care Med 2009; 37: 926-33.
19. Roberts JA, Kirkpatrick CM, Roberts MS et al. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009; 64:142-50.
20. Karjagin J, Lefeuvre S, Oselin K et al. Pharmacokinetics of meropenem determined by microdialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock. Clin Pharmacol Ther 2008; 83: 452-9.
21. Varghese JM, Jarrett P, Boots RJ et al. Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration. Int J Antimicrob Agents 2014; 43: 343-8.
22. Sauermann R, Delle-Karth G, Marsik C et al. Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients. Antimicrob Agents Chemother 2005; 49: 650-5.
23. Douglas A, Udy AA,Wallis SC et al. Plasma and tissue pharmacokinetics of cefazolin in patients undergoing elective and semielective abdominal aortic aneurysm open repair surgery. Antimicrob Agents Chemother 2011; 55: 5238-42.
24. Roberts JA, Roberts MS, Semark A et al. Antibiotic dosing in the 'at risk' critically ill patient: linking pathophysiology with pharmacokinetics/ pharmacodynamics in sepsis and trauma patients. BMC Anesthesiol 2011; 11: 3.
25. Bouw MR, Hammarlund-Udenaes M. Methodological aspects of the use of a calibrator in in vivo microdialysis-further development of the retrodialysis method. Pharm Res 1998; 15: 1673-9.
26. Tatarinova T, Neely M, Bartroff J et al. Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and nonparametric Bayesian. J Pharmacokinet Pharmacodyn 2013; 40: 189-99.
27. Neely MN, van Guilder MG, Yamada WM et al. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit 2012; 34: 467-76.
28. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10; quiz 11-2.
29. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2004; 2: 289-300.
30. Roberts JA, Pea F, Lipman J. The clinical relevance of plasma protein binding changes. Clin Pharmacokinet 2013; 52: 1-8.
31. Wong G, Briscoe S, Adnan S et al. Protein binding of b-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? Antimicrob Agents Chemother 2013; 57: 6165-70.
32. Bhalodi AA, Housman ST, Shepard A et al. Tissue pharmacokinetics of cefazolin in patients with lower limb infections. Antimicrob Agents Chemother 2013; 57: 5679-83.
33. Brill MJ, Houwink AP, Schmidt S et al. Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis. J Antimicrob Chemother 2014; 69:715-23.
34. Udy AA, Roberts JA, De Waele JJ et al. What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. Int J Antimicrob Agents 2012; 39: 455-7.
35. Roberts JA, Lipman J. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. Crit Care Med 2013; 41:489-95.